Wells Fargo analyst Larry Biegelsen lowered the firm’s price target on Tandem Diabetes (TNDM) to $13 from $20 and keeps an Equal Weight rating on the shares. The firm notes the company delivered an in-line quarter and updated its FY25 guidance, including a $25M-$30M cut to FY25 U.S. sales. Management pointed to increased competitive headwinds and slower rep ramp. The firm sees less visibility into 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes downgraded to Neutral from Overweight at Piper Sandler
- Tandem Diabetes Care Reports Record Q2 2025 Sales
- Tandem Diabetes Care: Strong Revenue Performance and Promising Portfolio Justify Buy Rating Despite Challenges
- Closing Bell Movers: DoorDash jumps 8%, Airbnb slips 6% on earnings
- Tandem Diabetes reports Q2 EPS (78c), consensus (40c)